You searched for "vascular"
UKEGS (UK and Éire Glaucoma Society) Conference 2024
9 October 2024
-10 October 2024
Pretty soon it’s going to be the 9th of October, and a quick Wikipedia search will tell you of how this day in history has seen the founding of the Kingdom of Valencia, the initial whispers of the Prague Astronomical...
Treat-and-extend regimen in treatment of patients with type 3 neovascularisation
5 October 2020
| Su Young
|
EYE - Vitreo-Retinal
Type 3 neovascularisation, also known as retinal angiomatous proliferation is a distinct subtype of neovascular AMD characterised by intraretinal neovascularisation. This retrospective study included 17 eyes diagnosed with type 3 neovascularisation who were changed from pro-re-nata (PRN) based treatment regime...
Learnings and trends in the management of open-angle and angle-closure glaucoma
1 August 2017
| Winifred Nolan, Nick Strouthidis, Keith Barton
|
EYE - Glaucoma
To be truly disruptive, newer technologies need to offer a quality of life benefit over medication to a broad population of glaucoma sufferers. Evidence and converging trends in medical and surgical management of glaucoma were explored in counterpoint discussions and...
Saccadic eye movements in young-onset Parkinson’s disease
5 August 2020
| Claire Howard
|
EYE - Neuro-ophthalmology
|
BOLD, Saccadic eye movements, fMRI, young onset Parkinson’s disease
The objective of this study was to understand control of saccadic eye movements in patients with young onset Parkinson’s disease (YOPD) where onset of disease symptoms appears early in life (<40 years of age). Functional magnetic resonance imaging (fMRI) was...
AI breakthrough brings geographic atrophy treatment a step closer
20 September 2021
A team led by Dr Konstantinos Balaskas at Moorfields Eye Hospital Reading Centre has developed a fully automated, deep-learning model (algorithm) that can detect and quantify geographic atrophy using standard optical coherence tomography (OCT) scans.
Managing cataract surgery in a patient with diabetic maculopathy
A 56-year-old type 2 diabetic with previously treated bilateral diabetic maculopathy develops a cataract requiring surgery in the right eye. He has had grid laser previously, followed intermittently by intravitreal triamcinalone, Avastin and more recently Lucentis in both eyes. His...Audiology and ophthalmology: A comparative perspective on diagnostics and patient care
4 December 2024
| Rosalyn Painter, Christopher Gordon, Anthony Vukic
|
EYE - Imaging, EYE - Vitreo-Retinal
I’m here with Chris Gordon and Anthony Vukic from Gloucestershire Hospitals NHS Foundation Trust to find out how two professions that may appear unrelated on the surface actually have a lot in common. Some of this article might surprise you....
Ocular bubbly: a vitreoretinal update on the art of gases
5 April 2022
| Adonis El Salloukh, Alexander Chiu, Sidath Wijetilleka
|
EYE - Vitreo-Retinal, EYE - General
The authors remind us of the revolutionary impact gases have had on retinal surgery. In 1938, Rosengren attempted to improve his retina repair surgical outcomes [1]. He discovered that suturing the retina or pressing externally on the sclera were not...
Adaptive optics imaging: resolving single cells in the living eye
1 June 2014
| Michel Michaelides (Prof), Adam Dubis
|
EYE - Cornea
The human retina is unique in the central nervous system (CNS) in that it can be directly visualised non-invasively. Technological advances of several imaging modalities, including optical coherence tomography (OCT), multichannel scanning laser ophthalmoscopy (SLO) and fundus photography, have afforded...
Lessons from an unusual case of syphilis
3 August 2023
| Ryian Mohamed, Shaman Dolly, Jonathan Than, Shweta Anand
|
EYE - Vitreo-Retinal
The rise of syphilis transmission rates over the past two decades has been one of public health’s great puzzles. In the UK, the situation has reached epidemic levels, with a 126% increase between 2013 and 2018 [1]. We present a...
Regulatory drug evaluations and expedited review initiatives: EU and US perspectives
1 April 2016
| Rod McNeil
|
EYE - General
The European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) each conduct independent assessments of benefit-risk profile when evaluating applications to market new or modified medicines, and their respective decision-making is guided by distinct legislation, procedures and...
